000			02099 a2200541 4500
005			20250516003715.0
264		0	_c20121130
008			201211s 0 0 eng d
022			_a1873-2496
024	7		_a10.1016/j.urolonc.2010.06.014 _2doi
040			_aNLM _beng _cNLM
100	1		_aFriedlander, Terence W
245	0	0	_aEffect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. _h[electronic resource]
260			_bUrologic oncology _c
300			_a408-14 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aDiarrhea _xchemically induced
650	0	4	_aDrug Administration Schedule
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aFatigue _xchemically induced
650	0	4	_aFlatulence _xchemically induced
650	0	4	_aHumans
650	0	4	_aInsulin-Like Growth Factor Binding Protein 1 _xblood
650	0	4	_aInsulin-Like Growth Factor Binding Protein 3 _xblood
650	0	4	_aInsulin-Like Growth Factor I _xanalysis
650	0	4	_aInsulin-Like Growth Factor II _xanalysis
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOctreotide _xadverse effects
650	0	4	_aOrchiectomy
650	0	4	_aPeptides _xblood
650	0	4	_aProstate-Specific Antigen _xblood
650	0	4	_aProstatic Neoplasms _xblood
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aWeinberg, Vivian K
700	1		_aSmall, Eric J
700	1		_aSharib, Jeremy
700	1		_aHarzstark, Andrea L
700	1		_aLin, Amy M
700	1		_aFong, Lawrence
700	1		_aRyan, Charles J
773	0		_tUrologic oncology _gvol. 30 _gno. 4 _gp. 408-14
856	4	0	_uhttps://doi.org/10.1016/j.urolonc.2010.06.014 _zAvailable from publisher's website
999			_c20212463 _d20212463